<DOC>
	<DOCNO>NCT00206687</DOCNO>
	<brief_summary>The purpose study explore safety , tolerability efficacy Spheramine ( culture human retinal pigment epithelial cell microcarriers ) Parkinson 's Disease patient advance disease insufficient symptom control optimum oral medication . Patients randomize receive Spheramine injection hemispheres sham surgical procedure ratio 1:1 . A three month pretreatment period must complete prior surgery . Time endpoint 24 month .</brief_summary>
	<brief_title>STEPS Trial - Spheramine Safety Efficacy Study</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Schering AG , Germany.Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. , Schering AG Germany rename Bayer Schering Pharma AG , Germany . Bayer HealthCare Pharmaceuticals , Inc.and Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Advanced Parkinson 's disease least 5 year Good response Ldopa Age 30 70 year Optimum oral therapy Tremor Dementia Very severe dyskinesia Previous brain surgery include deep brain stimulation Malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>